Xoma Corp. (XOMA) Stock Rating Reaffirmed by Wedbush
Xoma Corp. (NASDAQ:XOMA)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a report issued on Friday. They currently have a $3.00 price objective on the stock, up from their previous price objective of $1.42. Wedbush’s target price points to a potential upside of 459.28% from the company’s previous close.
Several other analysts have also recently commented on XOMA. Jefferies Group reissued a “hold” rating on shares of Xoma Corp. in a research note on Friday, August 5th. Cowen and Company restated a “neutral” rating on shares of Xoma Corp. in a report on Wednesday, August 10th. Finally, Zacks Investment Research lowered shares of Xoma Corp. from a “buy” rating to a “hold” rating in a report on Friday, August 26th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $1.81.
Xoma Corp. (NASDAQ:XOMA) opened at 0.5364 on Friday. The firm’s 50-day moving average is $0.61 and its 200 day moving average is $0.68. The stock has a market capitalization of $64.68 million, a PE ratio of 48.7636 and a beta of 2.70. Xoma Corp. has a 52-week low of $0.44 and a 52-week high of $2.03.
Xoma Corp. (NASDAQ:XOMA) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.84 million. During the same quarter last year, the company earned ($0.20) earnings per share. On average, equities analysts forecast that Xoma Corp. will post ($0.47) earnings per share for the current year.
A number of large investors have recently bought and sold shares of the company. Paloma Partners Management Co purchased a new stake in Xoma Corp. during the second quarter valued at $185,000. Spark Investment Management LLC raised its stake in Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares during the period. Vanguard Group Inc. raised its stake in Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares during the period. Wedbush Securities Inc. raised its stake in Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock valued at $223,000 after buying an additional 15,827 shares during the period. Finally, Bellevue Group AG purchased a new stake in Xoma Corp. during the first quarter valued at $174,000. Institutional investors own 17.13% of the company’s stock.
Xoma Corp. Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.